Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Refractory Solid Tumors

Refractory Solid Tumors

48

Pipeline Programs↗

30

Active Trials↗

55

Companies Involved↗

Refractory Solid Tumors is a moderately active landscape with 48 programs across 55 companies. The most active players are Immatics Biotechnologies GmbH, Sorrento Therapeutics, Inc..

Intelligence

Pipeline Metrics

Competitive Density

62/100

Pipeline Velocity

22/100

Mech. Concentration

9/100

Completion Rate

81/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Immatics Biotechnologies GmbH

2 programs

Sorrento Therapeutics, Inc.

1 program

Pipeline

Programs by Phase

Preclinical2

Xya02

XYone Therapeutics, Inc

PEEL-224

Peel Therapeutics Inc

Phase 120

Cabozantinib

Bristol-Myers Squibb

GV20-0251

GV20 Therapeutics

Second Generation 4-1BBζ EGFR806-Egfrt

Seattle Children's Hospital

STI-1386

Sorrento Therapeutics, Inc.

B7-H3CART Dose (intravenous)

Crystal Mackall, MD

Phase 226

Nivolumab

Bristol-Myers Squibb

Palbociclib

Pfizer

Irinotecan

Pfizer

Mitoxantrone Liposome

The First Affiliated Hospital of Soochow University

Devimistat

Northwestern University

Phase 3

No programs

Approved

No programs

Analysis

Modality Breakdown

75%

Small molecule

33 of 44 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 44 classified programs, each share of the total. Modality classified for 98% of 48 pipeline programs.

Analysis

Trial Status

189

clinical trials

Completed118 · 62%

Recruiting17 · 9%

Unknown status14 · 7%

Terminated13 · 7%

Withdrawn11 · 6%

Not yet recruiting7 · 4%

Other9 · 5%

Clinical Trials

Trial Activity

189 trials

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Combination With Hydroxyurea or Hydroxyurea/Atezolizumab in Treatment-refractory Solid Tumor Patients

Recruiting·BBionoxx Inc.·Phase 1·NCT07190833·27 enrolled

A Phase 1/2 Clinical Trial of the Novel Topoisomerase I Inhibitor PEEL-224 as a Single Agent and in Combination With Vincristine and Temozolomide in Children With Refractory, Progressive or Relapsed Solid Tumors

Recruiting·—·Preclinical·NCT06721689·59 enrolled

ELEVATE Study: A Phase II Single-Arm Open-Label Single-Center Exploratory Trial of Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Advanced Refractory Solid Tumors With EGFR-Positive

Recruiting·TTianjin Medical University Second Hospital·Phase 2·NCT07712029·32 enrolled

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors

Recruiting·—·Phase 1·NCT06500819·41 enrolled

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

Recruiting·IImmatics Biotechnologies GmbH·Phase 1·NCT05359445·95 enrolled

Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors

Recruiting·—·Phase 1·NCT03611595·18 enrolled

Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors

Recruiting·—·Phase 1·NCT06612645·9 enrolled

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06006273·48 enrolled

Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

Recruiting·WWashington University School of Medicine·Phase 1·NCT05521984·20 enrolled

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Recruiting·NNorthwestern University·Phase 2·NCT05733000·94 enrolled

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Recruiting·IImmatics US, Inc.·Phase 1/2·NCT03686124·375 enrolled

A Study of GV20-0251 in Advanced or Refractory Solid Tumors

Recruiting·WWest China Hospital·Phase 1·NCT07106827·10 enrolled

Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)

Recruiting·TTianjin Medical University Second Hospital·Phase 1/2·NCT06895733·65 enrolled

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT04796012·23 enrolled

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Recruiting·MMassachusetts General Hospital·Phase 1·NCT06302621·70 enrolled

Page 1 of 13

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)